Local Complications, Graft Thrombosis, Anastomotic Aneurysm, and Endovascular/Access Complication Rescue
Local vascular complications named by failure mode before rescue is chosen: graft thrombosis, anastomotic aneurysm, infection, pseudoaneurysm, and endovascular access disasters. The chapter frames the least morbid rescue that restores durable flow or seal for each failure pattern.
Choose a chapter overview or a specialist discussion. Each recording follows this published edition.
General medical education, not patient-specific advice.
Definition and presentation
Local vascular complications encompass failure of the reconstruction (, endoleak, ) or structural failure of the vessel and surrounding tissue (pseudoaneurysm, anastomotic , wound breakdown). The clinical presentation determines the urgency of rescue, ranging from an asymptomatic finding on surveillance imaging to acute or chronic limb-threatening ischemia ().
In CLTI, the diagnosis combines ischemic or tissue loss with confirmed peripheral artery disease, staged by the Wound, Ischemia, and foot Infection () system and mapped anatomically with the Global Limb Anatomic Staging System () .
Post-revascularization failure modes are specific to the index procedure:
- Open infrainguinal bypass: stenosis, anastomotic defect, inflow or outflow disease, thrombosis, anastomotic pseudoaneurysm, and surgical-site infection.
- Endovascular aortic repair (): endoleak (Types I through IV), sac expansion, migration, limb kinking, junctional separation, and limb-graft occlusion .
- Percutaneous access: bleeding, iatrogenic pseudoaneurysm, arteriovenous fistula, closure-device failure, and access thrombosis .
Surveillance and diagnosis
Detecting a failing reconstruction before it occludes or ruptures is the point of surveillance.
After lower-extremity revascularization, new symptoms or signs require clinical reassessment, ankle–brachial index and . For asymptomatic autogenous infrainguinal vein bypass, the 2024 guideline considers surveillance at 1–3 months, then 6 and 12 months and annually reasonable; the value of routine duplex after prosthetic bypass is uncertain. Revision requires a clinically and hemodynamically meaningful lesion, not any isolated stenosis greater than 50%. Earlier surveillance trials remain part of the historical evidence base, not proof of a universal threshold for all reconstructions .
Following EVAR, surveillance tracks sac size, leak type, sealing zones and device integrity. The SVS annual-duplex pathway after stable early imaging and the ESVS 2024 risk-stratified pathway should not be presented as identical. ESVS recommends early within 30 days and permits less frequent first-five-year imaging for selected low-risk standard repairs, while retaining long-term surveillance. New findings require reassessment and an interval appropriate to the actual failure risk, rather than automatic treatment of every type II leak . Polytetrafluoroethylene ()-based endografts exhibit a higher prevalence of Type II endoleak within one year than polyester-based devices; this higher prevalence necessitates rigorous imaging but does not trigger intervention without concurrent sac growth . Post-EVAR endoleaks or suspected failures on surveillance require computed tomography angiography (CTA) or adjunct imaging to map the anatomy and differentiate high-pressure seal failures from stable reperfusion .
Prevention and medical management
The 2014 Vascular Quality Initiative (VQI) registry remains useful background evidence on access complications, but coronary/TAVR closure comparisons and axillary-access series must not be pooled into one peripheral-intervention incidence or predictor claim . Contemporary primary evidence includes a 2025 series of covered-stent rescue in 41 patients with iatrogenic common-femoral injuries; it informs feasibility of rescue, not the incidence of injury or superiority over open repair . Ultrasound-guided percutaneous femoral artery access reduces hematoma, pseudoaneurysm, and arteriovenous fistula formation compared with landmark-guided puncture and is the standard of practice, especially in patients with obesity, scarring, or absent pulses .
Groin surgical-site infections convert an adequate reconstruction into prolonged morbidity. Transverse groin incisions yield fewer surgical-site infections and lymphoceles than vertical incisions in selected femoral artery exposures . The 2025 randomized trial of incisional negative-pressure therapy after femoral or hybrid procedures with groin incisions randomized 123 patients, of whom 109 completed the study, and found 30-day surgical-site infection in 15% versus 25% with gauze, without a statistically significant difference (P=0.340). This supports discussing wound risk, tolerability and device burden rather than promising a routine benefit; the trial does not establish equivalence or a proven high-risk subgroup effect .
Antithrombotic therapy following infrainguinal revascularization lowers graft thrombosis and major adverse limb events . In VOYAGER PAD, rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily reduced the composite of acute limb ischemia, major amputation, myocardial infarction, ischemic stroke, and cardiovascular death compared with aspirin alone at three years, with a corresponding increase in ISTH major bleeding . Systemic anticoagulation does not improve primary patency overall but is associated with better secondary patency in prosthetic conduits to below-knee targets, at the cost of higher wound complication rates .
Intervention triggers and treatment choice
Reintervention decisions integrate limb stage, anatomy, bleeding risk, and the failure mode. For infrapopliteal CLTI requiring revascularization, BASIL-2 demonstrated better amputation-free survival with a best-endovascular-first strategy than a vein-bypass-first strategy, driven primarily by differences in mortality . The earlier BASIL-1 data established foundational boundaries for severe limb ischemia; strategy selection must align with patient comorbidity, available conduit, and anatomic complexity .
BASIL-3 addresses a different choice: femoropopliteal endovascular treatment in CLTI, with or without additional infrapopliteal treatment. Neither a drug-coated balloon strategy nor primary drug-eluting stenting significantly improved amputation-free survival over plain balloon angioplasty with optional bare-metal stenting. It neither replaces BASIL-1/2 nor determines rescue of an acutely thrombosed bypass .
Putting the rescue decision in order
- Identify the index reconstruction and dominant failure: active bleeding, threatened-limb occlusion, failing-but-patent graft, pseudoaneurysm or aortic endoleak. Hemorrhage control and resuscitation take priority over a lengthy diagnostic pathway.
- For acute occlusion, assess sensory and motor function and arterial/venous Doppler signals immediately. A viable limb is not an automatic thrombolysis indication; an immediately threatened limb requires prompt reperfusion, and an irreversibly ischemic limb should not undergo futile revascularization .
- Choose the fastest suitable open, endovascular or hybrid reconstruction and correct the cause: alone does not repair an anastomotic stenosis, inadequate inflow, poor runoff or a kinked endograft. In Rutherford IIa, catheter-directed thrombolysis is an alternative to surgery; in selected IIb presentations it may be considered if started promptly, potentially with aspiration/thrombectomy, rather than being categorically prohibited .
- For pseudoaneurysm, assess active bleeding, infection, sac/neck anatomy, branch relationships and distal ischemia. Options include observation in selected stable cases, ultrasound-guided thrombin injection, covered-stent exclusion or open repair; size alone does not select the treatment. Covered-stent evidence is observational and common-femoral use may be outside labeling .
- Confirm hemostasis, inflow/outflow and distal perfusion; document the repaired failure mode and its follow-up plan. See Chapter 15 for access-specific rescue.
Failing but patent bypass
- Decision trigger
- New ischemic symptoms or confirmed hemodynamically important deterioration
- Treatment options and limits
- Define inflow, conduit, anastomosis and outflow disease before targeted endovascular or operative revision; an isolated >50% narrowing is not an automatic operation.
Acute graft occlusion, viable or marginally threatened limb
- Decision trigger
- Clinical viability, symptom duration and acceptable bleeding risk
- Treatment options and limits
- A viable limb without threat need not undergo lysis. For Rutherford IIa, consider catheter-directed lysis or surgery, with correction of the causative lesion.
Acute occlusion with immediate limb threat
- Decision trigger
- Sensory/motor deficit or rapidly worsening ischemia
- Treatment options and limits
- Prompt reperfusion by the fastest suitable open, endovascular or hybrid method; selected prompt lysis with thrombectomy is not excluded categorically.
Iatrogenic femoral pseudoaneurysm
- Decision trigger
- Symptoms, growth, bleeding, infection and ultrasound-defined neck/branch anatomy
- Treatment options and limits
- Ultrasound-guided thrombin injection when suitable; covered stent or open repair for selected unsuitable/failed cases. Do not make >2 cm alone a mandatory injection rule.
Complex or bleeding access injury
- Decision trigger
- Uncontrolled hemorrhage, ischemia, branch involvement or failed percutaneous treatment
- Treatment options and limits
- Endovascular balloon/covered-stent rescue or open repair according to anatomy and speed of control; infection and threatened skin/tissue may favor operative debridement/repair.
Anastomotic femoral pseudoaneurysm
- Decision trigger
- Structural anastomotic failure, with explicit infection assessment
- Treatment options and limits
- Open reconstruction or selected covered-stent exclusion in a hostile groin; retained infected material requires a source-control plan, not merely exclusion.
Catheter-directed thrombolysis for acute lower-extremity occlusion yields 89% one-month and 75% twelve-month amputation-free survival . STILE randomised catheter-directed lysis against surgery for non-embolic native and graft limb ischaemia and found no difference in death or major amputation; lysis reduced the magnitude of planned surgery and favoured symptom duration under 14 days, while surgery was superior beyond 14 days . TOPAS compared recombinant urokinase with primary surgery and gave similar amputation-free survival at 6 to 12 months with fewer subsequent open surgical procedures after lysis . Contraindications include stroke within 2 months, active bleeding, intracranial tumor, or systemic coagulopathy.
Type II endoleaks have a heterogeneous natural history, with roughly one-third resolving spontaneously, which supports observation until the sac grows .
Anatomic variants and specialized reconstructions
Endovascular limb-graft occlusion is strongly associated with hostile iliac anatomy, limb oversizing, and distal landing in a caliber-mismatched external iliac artery. Occlusion is managed via endovascular thrombolysis followed by adjunctive bare-metal stenting when anatomy permits .
During aortoiliac aneurysm repair, iliac branch devices are used to preserve hypogastric flow and prevent buttock or pelvic ischemia, showing established midterm technical success and branch patency .
In zone-2 thoracic endovascular aortic repair (), left subclavian artery revascularization is performed to mitigate the risk of stroke and spinal cord ischemia. Revascularization options include surgical bypass, surgical transposition, and endovascular strategies .
Areas of controversy
Covered stent-grafting is an option for selected anastomotic femoral pseudoaneurysms in patients at high operative risk. The reported patency in a small selected series does not establish comparative durability against open reconstruction or an advantage in an infected field. Infection and the need for definitive source control remain separate decisions .
Type II endoleak treatment remains controversial because spontaneous resolution, sac growth, occult type I/III leaks and recurrent filling after embolization complicate assessment of benefit. ESVS 2024 recommends considering intervention for significant sac growth of at least 10 mm only after excluding alternative causes (IIa C); a stable sac generally remains under surveillance. Technical embolization success does not by itself establish durable clinical benefit .
Saccular native aortic aneurysm is not synonymous with an anastomotic pseudoaneurysm. Exclude infection and assess symptoms and anatomy; earlier repair at a lower diameter than for a fusiform AAA may be considered, but there is no universal size offset or automatic repair of every small saccular lesion. See Chapter 18, “Treatment decisions and repair thresholds” .
Routine incisional negative-pressure therapy for every vascular groin incision is not established by the checked randomized trial. Its nonsignificant overall result does not exclude benefit in selected patients, but neither does it prove a high-risk subgroup advantage; wound risk and treatment burden should be considered explicitly .
BASIL-1 and BASIL-2 remain relevant to different initial revascularization decisions. BASIL-2 favored an endovascular-first strategy for its infrapopliteal CLTI population on the composite of major amputation or death, largely because of fewer deaths. It did not establish baseline cardiovascular comorbidity as the causal explanation for the randomized treatment difference, nor a universal strategy for graft-rescue procedures .
Further reading
- Non-Surgical treatment Versus Surgery for Iatrogenic Femoral Artery Pseudoaneurysms: Systematic Review and Meta-Analysis. (2022). Iatrogenic femoral pseudoaneurysm management.
- Systematic review of groin wound surgical site infection incidence after arterial intervention. (2023). Groin surgical-site infection after arterial intervention.
References
- 1.
- 2.
- 3.
- 4.2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. 2018.PubMed-indexed articleClinical practice guideline2017
2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. 2018. doi:10.1093/eurheartj/ehx095.
- 5.2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024.PubMed-indexed articleClinical practice guideline2024
2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease. Circulation. 2024. doi:10.1161/CIR.0000000000001251. PMID:38743805.
- 6.
- 7.
- 8.Prevalence of type II endoleak after elective endovascular aneurysm repair with polytetrafluoroethylene- or polyester-based endografts. Journal of vascular surgery. 2024.PubMed-indexed article2024
Prevalence of type II endoleak after elective endovascular aneurysm repair with polytetrafluoroethylene- or polyester-based endografts. Journal of vascular surgery. 2024. doi:10.1016/j.jvs.2023.09.019.
- 9.
- 10.
- 11.
- 12.Vascular complications of ProGlide versus Prostar in transcatheter aortic valve replacement (TAVR) procedures: meta-analysis.PubMed-indexed articleMeta-analysis / systematic review2023
Xiang Y, Chen C, Zhao J, Ma Y, Huang B, Wu Z. Vascular complications of ProGlide versus Prostar in transcatheter aortic valve replacement (TAVR) procedures: meta-analysis. BJS Open. 2023;7(4). doi:10.1093/bjsopen/zrad061. PMID:37498966.
- 13.Vascular Closure Devices For Axillary Artery Access: A Systematic Review and Meta-Analysis.PubMed-indexed articleMeta-analysis / systematic review2024
Koziarz A, Kennedy SA, Awad El-Karim G, Tan KT, Oreopoulos GD, Kalra S, et al. Vascular Closure Devices For Axillary Artery Access: A Systematic Review and Meta-Analysis. J Endovasc Ther. 2024;31(5):763-771. doi:10.1177/15266028221147451. PMID:36625294.
- 14.
- 15.
- 16.RETRACTED. The wound adjuncts effect of closed incision negative pressure wound therapy on stopping groin surgical site wound infection in arterial surgery: a meta-analysis DOI: 10.1111/iwj.14146 Retraction notice: PMID 39934959.
Retracted in 2025. Do not rely on this article as clinical evidence. Read the retraction notice
PubMed-indexed articleMeta-analysis / systematic review2023RETRACTED. The wound adjuncts effect of closed incision negative pressure wound therapy on stopping groin surgical site wound infection in arterial surgery: a meta-analysis DOI: 10.1111/iwj.14146 Retraction notice: doi:10.1111/iwj.70225; PMID 39934959.
- 17.
- 18.
- 19.Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency. Journal of vascular surgery. 2017.PubMed-indexed article2017
Comparative effectiveness of anticoagulation on midterm infrainguinal bypass graft patency. Journal of vascular surgery. 2017. doi:10.1016/j.jvs.2016.12.141.
- 20.A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2). Lancet. 2023.PubMed-indexed articleRandomized controlled trial2023
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2). Lancet. 2023. doi:10.1016/s0140-6736(23)00462-2
- 21.
- 22.
- 23.
- 24.Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection. Angiology. 2007.PubMed-indexed article2007
Treatment of iatrogenic femoral pseudoaneurysm by ultrasound-guided compression therapy and thrombin injection. Angiology. 2007. doi:10.1177/0003319706294608.
- 25.
- 26.Non-Surgical treatment Versus Surgery for Iatrogenic Femoral Artery Pseudoaneurysms: Systematic Review and Meta-Analysis. Front Surg. 2022.PubMed-indexed articleMeta-analysis / systematic review2022
Non-Surgical treatment Versus Surgery for Iatrogenic Femoral Artery Pseudoaneurysms: Systematic Review and Meta-Analysis. Front Surg. 2022. doi:10.3389/fsurg.2022.905701. PMID:36211300.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34.
- 35.Type II Endoleak after Endovascular Aneurysm Repair: Natural History and Treatment Outcomes. Annals of vascular surgery. 2017.PubMed-indexed article2017
Type II Endoleak after Endovascular Aneurysm Repair: Natural History and Treatment Outcomes. Annals of vascular surgery. 2017. doi:10.1016/j.avsg.2017.04.029.
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331.PubMed-indexed article2024
Wanhainen A, Van Herzeele I, Bastos Goncalves F, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Abdominal Aorto-Iliac Artery Aneurysms. Eur J Vasc Endovasc Surg. 2024;67(2):192-331. doi:10.1016/j.ejvs.2023.11.002.
- 42.Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2.PubMed-indexed article2018
Chaikof EL, Dalman RL, Eskandari MK, et al. The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg. 2018;67(1):2-77.e2. doi:10.1016/j.jvs.2017.10.044.
- 43.Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538.PubMed-indexed article1997
Rutherford RB, Baker JD, Ernst C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26(3):517-538. doi:10.1016/S0741-5214(97)70045-4.
- 44.Bjorck M, Earnshaw JJ, Acosta S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173-218.PubMed-indexed article2020
Bjorck M, Earnshaw JJ, Acosta S, et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg. 2020;59(2):173-218. doi:10.1016/j.ejvs.2019.09.006.
- 45.Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338(16):1105-1111.PubMed-indexed article1998
Ouriel K, Veith FJ, Sasahara AA. A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N Engl J Med. 1998;338(16):1105-1111. doi:10.1056/NEJM199804163381603.
- 46.The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220(3):251-268.PubMed-indexed article1994
The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220(3):251-268. doi:10.1097/00000658-199409000-00003.
- 47.
- 48.Prophylactic use of incisional negative pressure wound therapy for groin incisions in vascular surgery: randomized clinical trial 2025-06.PubMed-indexed article2025
Prophylactic use of incisional negative pressure wound therapy for groin incisions in vascular surgery: randomized clinical trial 2025-06. doi:10.1093/bjsopen/zraf059.
- 49.Plain balloon angioplasty with or without bare metal stenting versus drug coated balloon angioplasty with or without bare metal stenting versus primary drug eluting stenting in patients with chronic limb threatening ischaemia (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial 2025-02-24.PubMed-indexed article2025
Plain balloon angioplasty with or without bare metal stenting versus drug coated balloon angioplasty with or without bare metal stenting versus primary drug eluting stenting in patients with chronic limb threatening ischaemia (BASIL-3): open label, three arm, randomised, multicentre, phase 3 trial 2025-02-24. doi:10.1136/bmj-2024-080881.
Educational use only
AI assists this editorial workflow. Published updates are human-reviewed before publication.
Not intended to diagnose, monitor, predict, prognose, treat, or alleviate disease.
Verify clinically relevant information against primary sources and current guidelines.